Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA V: Review Model Evaluators Will Observe All FDA-Sponsor Meetings

This article was originally published in The Pink Sheet Daily

Executive Summary

Interim and final assessments will help determine which parts of the new, longer application review help FDA take more first-cycle actions.


Related Content

PDUFA V Reviews Are ‘Best Ever’ For Some Sponsors, Maybe Not FDA
PDUFA V ‘Program’ Gets Positive Evaluation – Except For Inspections
FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?
Learning From Its Successes? FDA Wants Feedback On All First-Cycle Actions For Assessment Program
Paging Dr. McClellan: FDA Calls On Brookings For PDUFA Research
“The Pink Sheet” DAILY – Most Notable Stories Of 2012
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
“Breakthrough” Designation Another Harmonization Opportunity, Woodcock Says
PDUFA V Commitment Letter Front-Loads Guidance, Meeting Milestones
NDA Review Pilot Will Be Mandatory, Assuming Program Flies At All





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts